Connect Biopharma, a loss-making clinical-stage biopharmaceutical firm, based in China, has filed for an initial public offering (IPO) to raise up to $100 million on Nasdaq.
Continue reading this premium story with a subscription to DealStreetAsia.
SubscribeAlready a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
